SAN ANTONIO, TX September 7, 2007 – Seno Medical Instruments, Inc. will announce the introduction of a new platform technology using opto-acoustics for small animal functional imaging at the Joint Molecular Imaging Conference in Providence, Rhode Island September 8-9.
The Joint Molecular Imaging Conference unites medical professionals and scientists with state of the art technology. Scientists and researchers from around the world will have the opportunity to learn about the Imagio™ research device that uses Seno’s patented laser opto-acoustic imaging technology.
Janet Campbell, CEO of Seno, recently announced a $2 (M) investment by the State of Texas’ Emerging Technology Fund.
“Our opto-acoustic technology will be presented for the first time as a commercial product as the Imagio™ research device. I am pleased that Seno has the opportunity to introduce this technology to such a distinguished group of researchers. Pharmaceutical and biotechnology companies will also be able to utilize Imagio™ for the acceleration of cancer research and drug discovery.” said Campbell.
Imagio™ technology produces real-time color images which distinguish between benign and malignant growths for all solid tumors and is expected to be a breakthrough for cancer detection. The research device produces detailed, full-scope images of small laboratory animals, such as nude mice. The image contrast is related to both blood volume and oxygenation status, allowing lesions to be diagnosed immediately. The new technology provides functional imaging information for cancer researchers, as well as the potential for cancer screening, diagnosis, and therapeutic treatments more humane than existing technologies.
In addition to the September 9 launch of the Imagio™ research device, to honor Conference participants Seno will also sponsor Waterfire Providence, an award winning fire sculpture exhibit and performance spanning three rivers that serves as a moving symbol of Providence’s renaissance. The event is recognized as one of “America’s 100 Best” by Reader’s Digest.